# The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination

> **NCT06751251** · — · ACTIVE_NOT_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Sarcoma
- Biomarkers
- Progression

## Interventions

- **DIAGNOSTIC_TEST:** IHC: Immunohistochemistry
- **GENETIC:** RNA-seq

## Key facts

- **NCT ID:** NCT06751251
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751251, "The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06751251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*